{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["COVID-19", "MD simulation", "RdRp", "SARS-CoV-2", "docking", "medicinal plants", "phytochemicals"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "38005857", "DateCompleted": {"Year": "2024", "Month": "01", "Day": "31"}, "DateRevised": {"Year": "2024", "Month": "05", "Day": "29"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "10", "Day": "30"}], "Language": ["eng"], "ELocationID": ["2175", "10.3390/v15112175"], "Journal": {"ISSN": "1999-4915", "JournalIssue": {"Volume": "15", "Issue": "11", "PubDate": {"Year": "2023", "Month": "Oct", "Day": "30"}}, "Title": "Viruses", "ISOAbbreviation": "Viruses"}, "ArticleTitle": "Covalent Inhibitors from Saudi Medicinal Plants Target RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2.", "Abstract": {"AbstractText": ["COVID-19, a disease caused by SARS-CoV-2, has caused a huge loss of human life, and the number of deaths is still continuing. Despite the lack of repurposed drugs and vaccines, the search for potential small molecules to inhibit SARS-CoV-2 is in demand. Hence, we relied on the drug-like characters of ten phytochemicals (compounds <b>1</b>-<b>10</b>) that were previously isolated and purified by our research team from Saudi medicinal plants. We computationally evaluated the inhibition of RNA-dependent RNA polymerase (RdRp) by compounds <b>1</b>-<b>10</b>. Non-covalent (reversible) docking of compounds <b>1</b>-<b>10</b> with RdRp led to the formation of a hydrogen bond with template primer nucleotides (A and U) and key amino acid residues (ASP623, LYS545, ARG555, ASN691, SER682, and ARG553) in its active pocket. Covalent (irreversible) docking revealed that compounds <b>7</b>, <b>8</b>, and <b>9</b> exhibited their irreversible nature of binding with CYS813, a crucial amino acid in the palm domain of RdRP. Molecular dynamic (MD) simulation analysis by RMSD, RMSF, and Rg parameters affirmed that RdRP complexes with compounds <b>7</b>, <b>8</b>, and <b>9</b> were stable and showed less deviation. Our data provide novel information on compounds <b>7</b>, <b>8</b>, and <b>9</b> that demonstrated their non-nucleoside and irreversible interaction capabilities to inhibit RdRp and shed new scaffolds as antivirals against SARS-CoV-2."]}, "AuthorList": [{"Identifier": ["0000-0002-0445-1357"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia."}], "LastName": "Bakheit", "ForeName": "Ahmed H", "Initials": "AH"}, {"Identifier": ["0000-0001-7030-3777"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zoology Department, College of Sciences, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia."}], "LastName": "Saquib", "ForeName": "Quaiser", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia."}], "LastName": "Ahmed", "ForeName": "Sarfaraz", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Botany & Microbiology Department, College of Sciences, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia."}], "LastName": "Ansari", "ForeName": "Sabiha M", "Initials": "SM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zoology Department, College of Sciences, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia."}], "LastName": "Al-Salem", "ForeName": "Abdullah M", "Initials": "AM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zoology Department, College of Sciences, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia."}], "LastName": "Al-Khedhairy", "ForeName": "Abdulaziz A", "Initials": "AA"}], "GrantList": [{"GrantID": "5-21-01-001-0025", "Agency": "This research was funded by King Abdulaziz City for Science and Technology (KACST) via the Fast Track Funding Path for COVID-19 Research Projects, grant number 5-21-01-001-0025.", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Viruses", "NlmUniqueID": "101509722", "ISSNLinking": "1999-4915"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Amino Acids"}, {"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}, {"RegistryNumber": "EC 2.7.7.48", "NameOfSubstance": "RNA-Dependent RNA Polymerase"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Amino Acids"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Antiviral Agents"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Dynamics Simulation"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "RNA-Dependent RNA Polymerase"}, {"QualifierName": ["drug effects"], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": [], "DescriptorName": "Saudi Arabia"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Bi Q., Wu Y., Mei S., Ye C., Zou X., Zhang Z., Liu X., Wei L., Truelove S.A., Zhang T., et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: A retrospective cohort study. Lancet Infect. Dis. 2020;20:911\u2013919. doi: 10.1016/S1473-3099(20)30287-5.", "ArticleIdList": ["10.1016/S1473-3099(20)30287-5", "PMC7185944", "32353347"]}, {"Citation": "Zhou P., Yang X.-L., Wang X.-G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang C.-L., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270\u2013273. doi: 10.1038/s41586-020-2012-7.", "ArticleIdList": ["10.1038/s41586-020-2012-7", "PMC7095418", "32015507"]}, {"Citation": "Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV) Biosci. Trends. 2020;14:69\u201371. doi: 10.5582/bst.2020.01020.", "ArticleIdList": ["10.5582/bst.2020.01020", "31996494"]}, {"Citation": "Fu D.-J., Li P., Song J., Zhang S.-Y., Xie H.-Z. Mechanisms of synergistic neurotoxicity induced by two high risk pesticide residues\u2014Chlorpyrifos and Carbofuran via oxidative stress. Toxicol. Vitr. 2019;54:338\u2013344. doi: 10.1016/j.tiv.2018.10.016.", "ArticleIdList": ["10.1016/j.tiv.2018.10.016", "30385350"]}, {"Citation": "WHO  WHO Coronavirus (COVID-19) Dashboard.  [(accessed on 9 October 2023)];2023  Available online:  https://covid19.who.int."}, {"Citation": "Monteleone G., Sarzi-Puttini P.C., Ardizzone S. Preventing COVID-19-induced pneumonia with anticytokine therapy. Lancet Rheumatol. 2020;2:e255\u2013e256. doi: 10.1016/S2665-9913(20)30092-8.", "ArticleIdList": ["10.1016/S2665-9913(20)30092-8", "PMC7193140", "32368737"]}, {"Citation": "Amaral-Machado L., Oliveira W.N., Rodrigues V.M., Albuquerque N.A., Alencar \u00c9.N., Egito E.S.T. Could natural products modulate early inflammatory responses, preventing acute respiratory distress syndrome in COVID-19-confirmed patients? Biomed. Pharmacother. 2021;134:111143. doi: 10.1016/j.biopha.2020.111143.", "ArticleIdList": ["10.1016/j.biopha.2020.111143", "PMC7832252", "33360048"]}, {"Citation": "Tang T., Bidon M., Jaimes J.A., Whittaker G.R., Daniel S. Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antivir. Res. 2020;178:104792. doi: 10.1016/j.antiviral.2020.104792.", "ArticleIdList": ["10.1016/j.antiviral.2020.104792", "PMC7194977", "32272173"]}, {"Citation": "Hoffmann M., Kleine-Weber H., Schroeder S., Kr\u00fcger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271\u2013280.e278. doi: 10.1016/j.cell.2020.02.052.", "ArticleIdList": ["10.1016/j.cell.2020.02.052", "PMC7102627", "32142651"]}, {"Citation": "Tortorici M.A., Veesler D. Chapter Four\u2014Structural insights into coronavirus entry. In: Rey F.A., editor. Advances in Virus Research. Volume 105. Academic Press; Cambridge, MA, USA: 2019. pp. 93\u2013116.", "ArticleIdList": ["PMC7112261", "31522710"]}, {"Citation": "Sungnak W., Huang N., B\u00e9cavin C., Berg M., Queen R., Litvinukova M., Talavera-L\u00f3pez C., Maatz H., Reichart D., Sampaziotis F., et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat. Med. 2020;26:681\u2013687. doi: 10.1038/s41591-020-0868-6.", "ArticleIdList": ["10.1038/s41591-020-0868-6", "PMC8637938", "32327758"]}, {"Citation": "Li X., Geng M., Peng Y., Meng L., Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J. Pharm. Anal. 2020;10:102\u2013108. doi: 10.1016/j.jpha.2020.03.001.", "ArticleIdList": ["10.1016/j.jpha.2020.03.001", "PMC7104082", "32282863"]}, {"Citation": "Das G., Das T., Chowdhury N., Chatterjee D., Bagchi A., Ghosh Z. Repurposed drugs and nutraceuticals targeting envelope protein: A possible therapeutic strategy against COVID-19. Genomics. 2021;113:1129\u20131140. doi: 10.1016/j.ygeno.2020.11.009.", "ArticleIdList": ["10.1016/j.ygeno.2020.11.009", "PMC7661923", "33189776"]}, {"Citation": "Nile S.H., Nile A., Qiu J., Li L., Jia X., Kai G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020;53:66\u201370. doi: 10.1016/j.cytogfr.2020.05.002.", "ArticleIdList": ["10.1016/j.cytogfr.2020.05.002", "PMC7204669", "32418715"]}, {"Citation": "Fehr A.R., Perlman S. Coronaviruses: An Overview of Their Replication and Pathogenesis. In: Maier H.J., Bickerton E., Britton P., editors. Coronaviruses: Methods and Protocols. Springer; New York, NY, USA: 2015. pp. 1\u201323.", "ArticleIdList": ["10.1007/978-1-4939-2438-7_1", "PMC4369385", "25720466"]}, {"Citation": "Jade D., Ayyamperumal S., Tallapaneni V., Joghee Nanjan C.M., Barge S., Mohan S., Nanjan M.J. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PLPRO and 3CLPRO proteases. Eur. J. Pharmacol. 2021;901:174082. doi: 10.1016/j.ejphar.2021.174082.", "ArticleIdList": ["10.1016/j.ejphar.2021.174082", "PMC8018918", "33823185"]}, {"Citation": "Tumskiy R.S., Tumskaia A.V., Klochkova I.N., Richardson R.J. SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations. Comput. Biol. Med. 2023;153:106449. doi: 10.1016/j.compbiomed.2022.106449.", "ArticleIdList": ["10.1016/j.compbiomed.2022.106449", "PMC9788855", "36586228"]}, {"Citation": "Lu J., Lu W., Jiang H., Yang C., Dong X. Molecular Docking and Dynamics of Phytochemicals From Chinese Herbs with SARS-CoV-2 RdRp. Nat. Prod. Commun. 2022;17:1934578X221105693. doi: 10.1177/1934578X221105693.", "ArticleIdList": ["10.1177/1934578X221105693"]}, {"Citation": "Nesterenko P.A., McLaughlin J., Tsai B.L., Burton Sojo G., Cheng D., Zhao D., Mao Z., Bangayan N.J., Obusan M.B., Su Y., et al. HLA-A\u221702:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses. Cell Rep. 2021;37:110167. doi: 10.1016/j.celrep.2021.110167.", "ArticleIdList": ["10.1016/j.celrep.2021.110167", "PMC8660260", "34919800"]}, {"Citation": "Zhang L.-C., Zhao H.-L., Liu J., He L., Yu R.-L., Kang C.-M. Design of SARS-CoV-2 Mpro, PLpro dual-target inhibitors based on deep reinforcement learning and virtual screening. Future Med. Chem. 2022;14:393\u2013405. doi: 10.4155/fmc-2021-0269.", "ArticleIdList": ["10.4155/fmc-2021-0269", "PMC8920029", "35220726"]}, {"Citation": "Glab-ampai K., Kaewchim K., Thavorasak T., Saenlom T., Thepsawat W., Mahasongkram K., Thueng-In K., Sookrung N., Chaicumpa W., Chulanetra M. Targeting Emerging RNA Viruses by Engineered Human Superantibody to Hepatitis C Virus RNA-Dependent RNA Polymerase. Front. Microbiol. 2022;13:926929. doi: 10.3389/fmicb.2022.926929.", "ArticleIdList": ["10.3389/fmicb.2022.926929", "PMC9355540", "35935185"]}, {"Citation": "Aziz S., Waqas M., Mohanta T.K., Halim S.A., Iqbal A., Ali A., Khalid A., Abdalla A.N., Khan A., Al-Harrasi A. Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation. J. Infect. Public Health. 2023;16:501\u2013519. doi: 10.1016/j.jiph.2023.02.009.", "ArticleIdList": ["10.1016/j.jiph.2023.02.009", "PMC9927802", "36801630"]}, {"Citation": "Furuta Y., Takahashi K., Kuno-Maekawa M., Sangawa H., Uehara S., Kozaki K., Nomura N., Egawa H., Shiraki K. Mechanism of Action of T-705 against Influenza Virus. Antimicrob. Agents Chemother. 2005;49:981\u2013986. doi: 10.1128/AAC.49.3.981-986.2005.", "ArticleIdList": ["10.1128/AAC.49.3.981-986.2005", "PMC549233", "15728892"]}, {"Citation": "Furuta Y., Komeno T., Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B. 2017;93:449\u2013463. doi: 10.2183/pjab.93.027.", "ArticleIdList": ["10.2183/pjab.93.027", "PMC5713175", "28769016"]}, {"Citation": "Graci J.D., Cameron C.E. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 2006;16:37\u201348. doi: 10.1002/rmv.483.", "ArticleIdList": ["10.1002/rmv.483", "PMC7169142", "16287208"]}, {"Citation": "De Clercq E., Li G. Approved Antiviral Drugs over the Past 50 Years. Clin. Microbiol. Rev. 2016;29:695\u2013747. doi: 10.1128/cmr.00102-15.", "ArticleIdList": ["10.1128/cmr.00102-15", "PMC4978613", "27281742"]}, {"Citation": "Noshi T., Kitano M., Taniguchi K., Yamamoto A., Omoto S., Baba K., Hashimoto T., Ishida K., Kushima Y., Hattori K., et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antivir. Res. 2018;160:109\u2013117. doi: 10.1016/j.antiviral.2018.10.008.", "ArticleIdList": ["10.1016/j.antiviral.2018.10.008", "30316915"]}, {"Citation": "Clark M.P., Ledeboer M.W., Davies I., Byrn R.A., Jones S.M., Perola E., Tsai A., Jacobs M., Nti-Addae K., Bandarage U.K., et al. Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2. J. Med. Chem. 2014;57:6668\u20136678. doi: 10.1021/jm5007275.", "ArticleIdList": ["10.1021/jm5007275", "25019388"]}, {"Citation": "Lemm Julie A., Liu M., Gentles Robert G., Ding M., Voss S., Pelosi Lenore A., Wang Y.-K., Rigat Karen L., Mosure Kathleen W., Bender John A., et al. Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase. Antimicrob. Agents Chemother. 2014;58:3485\u20133495. doi: 10.1128/aac.02495-13.", "ArticleIdList": ["10.1128/aac.02495-13", "PMC4068470", "24733465"]}, {"Citation": "Cer\u00f3n-Carrasco J.P. When Virtual Screening Yields Inactive Drugs: Dealing with False Theoretical Friends. ChemMedChem. 2022;17:e202200278. doi: 10.1002/cmdc.202200278.", "ArticleIdList": ["10.1002/cmdc.202200278", "PMC9542010", "35726731"]}, {"Citation": "Kumar S., Kashyap P., Chowdhury S., Kumar S., Panwar A., Kumar A. Identification of phytochemicals as potential therapeutic agents that binds to Nsp15 protein target of coronavirus (SARS-CoV-2) that are capable of inhibiting virus replication. Phytomedicine. 2020;85:153317. doi: 10.1016/j.phymed.2020.153317.", "ArticleIdList": ["10.1016/j.phymed.2020.153317", "PMC7470885", "32943302"]}, {"Citation": "Mani J.S., Johnson J.B., Steel J.C., Broszczak D.A., Neilsen P.M., Walsh K.B., Naiker M. Natural product-derived phytochemicals as potential agents against coronaviruses: A review. Virus Res. 2020;284:197989. doi: 10.1016/j.virusres.2020.197989.", "ArticleIdList": ["10.1016/j.virusres.2020.197989", "PMC7190535", "32360300"]}, {"Citation": "Ho T.Y., Wu S.L., Chen J.C., Li C.C., Hsiang C.Y. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antivir. Res. 2007;74:92\u2013101. doi: 10.1016/j.antiviral.2006.04.014.", "ArticleIdList": ["10.1016/j.antiviral.2006.04.014", "PMC7114332", "16730806"]}, {"Citation": "Gowrishankar S., Muthumanickam S., Kamaladevi A., Karthika C., Jothi R., Boomi P., Maniazhagu D., Pandian S.K. Promising phytochemicals of traditional Indian herbal steam inhalation therapy to combat COVID-19\u2014An in silico study. Food Chem. Toxicol. 2021;148:111966. doi: 10.1016/j.fct.2020.111966.", "ArticleIdList": ["10.1016/j.fct.2020.111966", "PMC7780060", "33412235"]}, {"Citation": "Panikar S., Shoba G., Arun M., Sahayarayan J.J., Nanthini A.U.R., Chinnathambi A., Alharbi S.A., Nasif O., Kim H.-J. Essential oils as an effective alternative for the treatment of COVID-19: Molecular interaction analysis of protease (Mpro) with pharmacokinetics and toxicological properties. J. Infect. Public Health. 2021 doi: 10.1016/j.jiph.2020.12.037.", "ArticleIdList": ["10.1016/j.jiph.2020.12.037", "PMC7874929", "33848890"]}, {"Citation": "Parida P.K., Paul D., Chakravorty D. Nature\u2019s therapy for COVID-19: Targeting the vital non-structural proteins (NSP) from SARS-CoV-2 with phytochemicals from Indian medicinal plants. Phytomed. Plus. 2021;1:100002. doi: 10.1016/j.phyplu.2020.100002.", "ArticleIdList": ["10.1016/j.phyplu.2020.100002", "PMC7691168", "35403083"]}, {"Citation": "Azeem M., Mustafa G., Mahrosh H.S. Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies. Int. J. Immunopathol. Pharmacol. 2022;36:3946320221142793. doi: 10.1177/03946320221142793.", "ArticleIdList": ["10.1177/03946320221142793", "PMC9716588", "36442514"]}, {"Citation": "Chen T.-H., Tsai M.-J., Chang C.-S., Xu L., Fu Y.-S., Weng C.-F. The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion. J. Infect. Public Health. 2023;16:42\u201354. doi: 10.1016/j.jiph.2022.11.022.", "ArticleIdList": ["10.1016/j.jiph.2022.11.022", "PMC9675089", "36470006"]}, {"Citation": "Rajak P., Ganguly A. In silico study unfolds inhibitory potential of epicatechin gallate against SARS-CoV-2 entry and replication within the host cell. Mechanobiol. Med. 2023;1:100015. doi: 10.1016/j.mbm.2023.100015.", "ArticleIdList": ["10.1016/j.mbm.2023.100015"]}, {"Citation": "Ahmed S., Al-Rehaily A.J., Ahmad M.S., Yousaf M., Nur-e-Alam M., Parvez M.K., Al-Dosari M.S., Noman O.M., Khan S.I., Khan I.A. Chemical constituents from Oncocalyx glabratus and their biological activities. Phytochem. Lett. 2017;20:128\u2013132. doi: 10.1016/j.phytol.2017.04.016.", "ArticleIdList": ["10.1016/j.phytol.2017.04.016"]}, {"Citation": "Ahmed S., Al-Rehaily A.J., Ahmad M.S., Yousaf M., Nur-e-Alam M., Thomas J., Khan S.I., Khan I.A. Cytotoxic and antiinflammatory activities of the chemical constituents isolated from Baccharoides schimperi DC. S. Afr. J. Bot. 2018;114:9\u201313. doi: 10.1016/j.sajb.2017.10.007.", "ArticleIdList": ["10.1016/j.sajb.2017.10.007"]}, {"Citation": "Ahmed S., Mothana R., Yousaf M., Al-Rehaily A. Activity guided isolation of chemical constituents from the biologically active methanol extract of Euphorbia schimperi c. presl. Bull. Chem. Soc. Ethiop. 2017;31:471\u2013479. doi: 10.4314/bcse.v31i3.11.", "ArticleIdList": ["10.4314/bcse.v31i3.11"]}, {"Citation": "ChemAxon.  [(accessed on 3 September 2023)].  Available online:  https://chemaxon.com/marvin."}, {"Citation": "Mesecar A.D. Structure of COVID-19 main protease bound to potent broad-spectrum non-covalent inhibitor X77. Protein Data Bank. 2020 doi: 10.2210/pdb6W63/pdb.", "ArticleIdList": ["10.2210/pdb6W63/pdb"]}, {"Citation": "Khalaf H.S., Naglah A.M., Al-Omar M.A., Moustafa G.O., Awad H.M., Bakheit A.H. Synthesis, Docking, Computational Studies, and Antimicrobial Evaluations of New Dipeptide Derivatives Based on Nicotinoylglycylglycine Hydrazide. Molecules. 2020;25:3589. doi: 10.3390/molecules25163589.", "ArticleIdList": ["10.3390/molecules25163589", "PMC7464391", "32784576"]}, {"Citation": "Al-Khodairy F.M., Khan M.K.A., Kunhi M., Pulicat M.S., Akhtar S., Arif J.M. In Silico prediction of mechanism of Erysolin-induced apoptosis in human breast cancer cell lines. Am. J. Bioinform. Res. 2013;3:62\u201371."}, {"Citation": "Labute P. Protonate3D: Assignment of ionization states and hydrogen coordinates to macromolecular structures. Proteins Struct. Funct. Bioinform. 2009;75:187\u2013205. doi: 10.1002/prot.22234.", "ArticleIdList": ["10.1002/prot.22234", "PMC3056144", "18814299"]}, {"Citation": "Cuesta A., Wan X., Burlingame A.L., Taunton J. Ligand Conformational Bias Drives Enantioselective Modification of a Surface-Exposed Lysine on Hsp90. J. Am. Chem. Soc. 2020;142:3392\u20133400. doi: 10.1021/jacs.9b09684.", "ArticleIdList": ["10.1021/jacs.9b09684", "32009391"]}, {"Citation": "Wojciechowski M., Lesyng B. Generalized Born Model:\u2009 Analysis, Refinement, and Applications to Proteins. J. Phys. Chem. B. 2004;108:18368\u201318376. doi: 10.1021/jp046748b.", "ArticleIdList": ["10.1021/jp046748b"]}, {"Citation": "Corbeil C.R., Williams C.I., Labute P. Variability in docking success rates due to dataset preparation. J. Comput.-Aided Mol. Des. 2012;26:775\u2013786. doi: 10.1007/s10822-012-9570-1.", "ArticleIdList": ["10.1007/s10822-012-9570-1", "PMC3397132", "22566074"]}, {"Citation": "Na\u00efm M., Bhat S., Rankin K.N., Dennis S., Chowdhury S.F., Siddiqi I., Drabik P., Sulea T., Bayly C.I., Jakalian A., et al. Solvated Interaction Energy (SIE) for Scoring Protein\u2212Ligand Binding Affinities. 1. Exploring the Parameter Space. J. Chem. Inf. Model. 2007;47:122\u2013133. doi: 10.1021/ci600406v.", "ArticleIdList": ["10.1021/ci600406v", "17238257"]}, {"Citation": "Phillips J.C., Braun R., Wang W., Gumbart J., Tajkhorshid E., Villa E., Chipot C., Skeel R.D., Kal\u00e9 L., Schulten K. Scalable molecular dynamics with NAMD. J. Comput. Chem. 2005;26:1781\u20131802. doi: 10.1002/jcc.20289.", "ArticleIdList": ["10.1002/jcc.20289", "PMC2486339", "16222654"]}, {"Citation": "Jo S., Kim T., Iyer V.G., Im W. CHARMM-GUI: A web-based graphical user interface for CHARMM. J. Comput. Chem. 2008;29:1859\u20131865. doi: 10.1002/jcc.20945.", "ArticleIdList": ["10.1002/jcc.20945", "18351591"]}, {"Citation": "CHARMM General Force Field (CGenFF)  [(accessed on 3 September 2023)].  Available online:  https://cgenff.silcsbio.com."}, {"Citation": "Yu W., He X., Vanommeslaeghe K., MacKerell A.D., Jr. Extension of the CHARMM general force field to sulfonyl-containing compounds and its utility in biomolecular simulations. J. Comput. Chem. 2012;33:2451\u20132468. doi: 10.1002/jcc.23067.", "ArticleIdList": ["10.1002/jcc.23067", "PMC3477297", "22821581"]}, {"Citation": "Vanommeslaeghe K., Hatcher E., Acharya C., Kundu S., Zhong S., Shim J., Darian E., Guvench O., Lopes P., Vorobyov I., et al. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 2010;31:671\u2013690. doi: 10.1002/jcc.21367.", "ArticleIdList": ["10.1002/jcc.21367", "PMC2888302", "19575467"]}, {"Citation": "Boonstra S., Onck P.R., Giessen E.v.d. CHARMM TIP3P Water Model Suppresses Peptide Folding by Solvating the Unfolded State. J. Phys. Chem. B. 2016;120:3692\u20133698. doi: 10.1021/acs.jpcb.6b01316.", "ArticleIdList": ["10.1021/acs.jpcb.6b01316", "27031562"]}, {"Citation": "Gao X., Qin B., Chen P., Zhu K., Hou P., Wojdyla J.A., Wang M., Cui S. Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm. Sin. B. 2021;11:237\u2013245. doi: 10.1016/j.apsb.2020.08.014.", "ArticleIdList": ["10.1016/j.apsb.2020.08.014", "PMC7467110", "32895623"]}, {"Citation": "Ghazwani M.Y., Bakheit A.H., Hakami A.R., Alkahtani H.M., Almehizia A.A. Virtual Screening and Molecular Docking Studies for Discovery of Potential RNA-Dependent RNA Polymerase Inhibitors. Crystals. 2021;11:471. doi: 10.3390/cryst11050471.", "ArticleIdList": ["10.3390/cryst11050471"]}, {"Citation": "Naydenova K., Muir K.W., Wu L.-F., Zhang Z., Coscia F., Peet M.J., Castro-Hartmann P., Qian P., Sader K., Dent K., et al. Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP. Proc. Natl. Acad. Sci. USA. 2021;118:e2021946118. doi: 10.1073/pnas.2021946118.", "ArticleIdList": ["10.1073/pnas.2021946118", "PMC7896311", "33526596"]}, {"Citation": "Shitrit A., Zaidman D., Kalid O., Bloch I., Doron D., Yarnizky T., Buch I., Segev I., Ben-Zeev E., Segev E., et al. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Sci. Rep. 2020;10:20808. doi: 10.1038/s41598-020-77794-5.", "ArticleIdList": ["10.1038/s41598-020-77794-5", "PMC7704658", "33257760"]}, {"Citation": "Hassam M., Bashir M.A., Shafi S., Zahra N.-u.-A., Khan K., Jalal K., Siddiqui H., Uddin R. Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro. Comput. Biol. Med. 2022;151:106284. doi: 10.1016/j.compbiomed.2022.106284.", "ArticleIdList": ["10.1016/j.compbiomed.2022.106284", "PMC9635257", "36370580"]}, {"Citation": "Dampalla C.S., Miller M.J., Kim Y., Zabiegala A., Nguyen H.N., Madden T.K., Thurman H.A., Machen A.J., Cooper A., Liu L., et al. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV) Eur. J. Med. Chem. 2023;254:115376. doi: 10.1016/j.ejmech.2023.115376.", "ArticleIdList": ["10.1016/j.ejmech.2023.115376", "PMC10105399", "37080108"]}, {"Citation": "Brindani N., Munaf\u00f2 F., Menichetti A., Donati E., Nigro M., Ottonello G., Armirotti A., De Vivo M. Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors. Biorg. Med. Chem. 2023;80:117179. doi: 10.1016/j.bmc.2023.117179.", "ArticleIdList": ["10.1016/j.bmc.2023.117179", "PMC9862713", "36716583"]}, {"Citation": "WHO  Tracking SARS-CoV-2 Variants.  [(accessed on 9 October 2023)];2023  Available online:  https://www.who.int/activities/tracking-SARS-CoV-2-variants."}, {"Citation": "Taylor P.C., Adams A.C., Hufford M.M., de la Torre I., Winthrop K., Gottlieb R.L. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 2021;21:382\u2013393. doi: 10.1038/s41577-021-00542-x.", "ArticleIdList": ["10.1038/s41577-021-00542-x", "PMC8054133", "33875867"]}, {"Citation": "US FDA  COVID-19 Vaccines.  [(accessed on 9 October 2023)];2019  Available online:  https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines."}, {"Citation": "Byl\u00e9hn F., Men\u00e9ndez C.A., Perez-Lemus G.R., Alvarado W., de Pablo J.J. Modeling the Binding Mechanism of Remdesivir, Favilavir, and Ribavirin to SARS-CoV-2 RNA-Dependent RNA Polymerase. ACS Cent. Sci. 2021;7:164\u2013174. doi: 10.1021/acscentsci.0c01242.", "ArticleIdList": ["10.1021/acscentsci.0c01242", "PMC7805600", "33527086"]}, {"Citation": "Tian L., Pang Z., Li M., Lou F., An X., Zhu S., Song L., Tong Y., Fan H., Fan J. Molnupiravir and Its Antiviral Activity Against COVID-19. Front. Immunol. 2022;13:855496. doi: 10.3389/fimmu.2022.855496.", "ArticleIdList": ["10.3389/fimmu.2022.855496", "PMC9013824", "35444647"]}, {"Citation": "Duveau D.Y., Thomas C.J. The Remarkable Selectivity of Nirmatrelvir. ACS Pharmacol. Transl. Sci. 2022;5:445\u2013447. doi: 10.1021/acsptsci.2c00065.", "ArticleIdList": ["10.1021/acsptsci.2c00065", "PMC9128007", "35702394"]}, {"Citation": "McLean G., Kamil J., Lee B., Moore P., Schulz Thomas F., Muik A., Sahin U., T\u00fcreci \u00d6., Pather S. The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. mBio. 2022;13:e02979-21. doi: 10.1128/mbio.02979-21.", "ArticleIdList": ["10.1128/mbio.02979-21", "PMC9040821", "35352979"]}, {"Citation": "Corti D., Purcell L.A., Snell G., Veesler D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021;184:3086\u20133108. doi: 10.1016/j.cell.2021.05.005.", "ArticleIdList": ["10.1016/j.cell.2021.05.005", "PMC8152891", "34087172"]}, {"Citation": "ASPR, Administration for Strategic Preparedness & Response, FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults.  [(accessed on 9 October 2023)];2023  Available online:  https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults."}, {"Citation": "Lee T.C., Morris A.M., Grover S.A., Murthy S., McDonald E.G. Outpatient Therapies for COVID-19: How Do We Choose? Open Forum Infect. Dis. 2022;9:ofac008. doi: 10.1093/ofid/ofac008.", "ArticleIdList": ["10.1093/ofid/ofac008", "PMC8807279", "35165657"]}, {"Citation": "ASPR, Administration for Strategic Preparedness & Response, Side-by-Side Overview of Therapeutics Authorized or Approved for the Treatment of Mild to Moderate COVID-19.  [(accessed on 9 October 2023)];2023  Available online:  https://aspr.hhs.gov/COVID-19/Therapeutics/Documents/side-by-side-overview.pdf."}, {"Citation": "Zhang Y.-N., Zhu G.-H., Liu W., Xiong Y., Hu Q., Zhuang X.-Y., Jia G.-H., Zhang W.-D., Ge G.-B. Discovery and characterization of the covalent SARS-CoV-2 3CLpro inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches. Phytomedicine. 2023;114:154796. doi: 10.1016/j.phymed.2023.154796.", "ArticleIdList": ["10.1016/j.phymed.2023.154796", "PMC10052880", "37037086"]}, {"Citation": "Barhouchi B., Menacer R., Bouchkioua S., Mansour A., Belattar N. Compounds from myrtle flowers as antibacterial agents and SARS-CoV-2 inhibitors: In-vitro and molecular docking studies. Arab. J. Plant. Prot. 2023;16:104939. doi: 10.1016/j.arabjc.2023.104939.", "ArticleIdList": ["10.1016/j.arabjc.2023.104939", "PMC10140470", "37193561"]}, {"Citation": "Hossain A., Rahman M.E., Rahman M.S., Nasirujjaman K., Matin M.N., Faruqe M.O., Rabbee M.F. Identification of medicinal plant-based phytochemicals as a potential inhibitor for SARS-CoV-2 main protease (Mpro) using molecular docking and deep learning methods. Comput. Biol. Med. 2023;157:106785. doi: 10.1016/j.compbiomed.2023.106785.", "ArticleIdList": ["10.1016/j.compbiomed.2023.106785", "PMC10008098", "36931201"]}, {"Citation": "Parihar A., Sonia Z.F., Akter F., Ali M.A., Hakim F.T., Hossain M.S. Phytochemicals-based targeting RdRp and main protease of SARS-CoV-2 using docking and steered molecular dynamic simulation: A promising therapeutic approach for Tackling COVID-19. Comput. Biol. Med. 2022;145:105468. doi: 10.1016/j.compbiomed.2022.105468.", "ArticleIdList": ["10.1016/j.compbiomed.2022.105468", "PMC8964014", "35390745"]}, {"Citation": "Guimar\u00e3es Santana B.C., de Almeida Marques D.P., dos Santos Freitas A., Ferreira M.M., de Sousa Lopes D., Bagno F.F., Guimar\u00e3es da Fonseca F., dos Reis J.G.A.C., Oliveira Mendes T.A.d., Santos J.L.d., et al. Protease inhibitors from Theobroma cacao impair SARS-CoV-2 replication in vitro. Heliyon. 2023;9:e15860. doi: 10.1016/j.heliyon.2023.e15860.", "ArticleIdList": ["10.1016/j.heliyon.2023.e15860", "PMC10155420", "37153407"]}, {"Citation": "Ahmad J., Ikram S., Ahmad F., Rehman I.U., Mushtaq M. SARS-CoV-2 RNA Dependent RNA polymerase (RdRp)\u2014A drug repurposing study. Heliyon. 2020;6:e04502. doi: 10.1016/j.heliyon.2020.e04502.", "ArticleIdList": ["10.1016/j.heliyon.2020.e04502", "PMC7377705", "32754651"]}, {"Citation": "Gao S., Song L., Xu H., Fikatas A., Oeyen M., De Jonghe S., Zhao F., Jing L., Jochmans D., Vangeel L., et al. Identification of Polyphenol Derivatives as Novel SARS-CoV-2 and DENV Non-Nucleoside RdRp Inhibitors. Molecules. 2023;28:160. doi: 10.3390/molecules28010160.", "ArticleIdList": ["10.3390/molecules28010160", "PMC9822497", "36615354"]}, {"Citation": "Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q., Ming Z., Zhang L., et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020;368:779\u2013782. doi: 10.1126/science.abb7498.", "ArticleIdList": ["10.1126/science.abb7498", "PMC7164392", "32277040"]}, {"Citation": "Yin W., Mao C., Luan X., Shen D.-D., Shen Q., Su H., Wang X., Zhou F., Zhao W., Gao M., et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020;368:1499\u20131504. doi: 10.1126/science.abc1560.", "ArticleIdList": ["10.1126/science.abc1560", "PMC7199908", "32358203"]}, {"Citation": "Padhi A.K., Shukla R., Saudagar P., Tripathi T. High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: Implications for potential resistance. iScience. 2021;24:101992. doi: 10.1016/j.isci.2020.101992.", "ArticleIdList": ["10.1016/j.isci.2020.101992", "PMC7807151", "33490902"]}, {"Citation": "Gado S., ALAG\u00d6Z Z. RNA-DEPENDENT RNA POLYMERASE (RDRP) INHIBITOR DRUGS AGAINST SARS-COV-2: A MOLECULAR DOCKING STUDY SARS-COV-2\u2019YE KAR\u015eI RNA-BA\u011eIMLI RNA POL\u0130MERAZ (RDRP) \u0130NH\u0130B\u0130T\u00d6R \u0130LA\u00c7LARI: B\u0130R MOLEK\u00dcLER DOCK\u0130NG \u00c7ALI\u015eMASI. Ank. Univ. Eczaci. Fak. Derg. 2022;46:62\u201377. doi: 10.33483/jfpau.963384.", "ArticleIdList": ["10.33483/jfpau.963384"]}, {"Citation": "Gordon C.J., Tchesnokov E.P., Woolner E., Perry J.K., Feng J.Y., Porter D.P., G\u00f6tte M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 2020;295:6785\u20136797. doi: 10.1074/jbc.RA120.013679.", "ArticleIdList": ["10.1074/jbc.RA120.013679", "PMC7242698", "32284326"]}, {"Citation": "Koulgi S., Jani V., Uppuladinne M.V.N., Sonavane U., Joshi R. Natural plant products as potential inhibitors of RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2. PLoS ONE. 2021;16:e0251801. doi: 10.1371/journal.pone.0251801.", "ArticleIdList": ["10.1371/journal.pone.0251801", "PMC8118514", "33984041"]}, {"Citation": "Boadu A., Agoni C., Karpoormath R., Soliman M., Nlooto M. Repurposing antiviral phytochemicals from the leaf extracts of Spondias mombin (Linn) towards the identification of potential SARSCOV-2 inhibitors. Sci. Rep. 2022;12:10896. doi: 10.1038/s41598-022-14558-3.", "ArticleIdList": ["10.1038/s41598-022-14558-3", "PMC9240089", "35764663"]}, {"Citation": "Scarpino A., Ferenczy G.G., Keser\u0171 G.M. Comparative Evaluation of Covalent Docking Tools. J. Chem. Inf. Model. 2018;58:1441\u20131458. doi: 10.1021/acs.jcim.8b00228.", "ArticleIdList": ["10.1021/acs.jcim.8b00228", "29890081"]}, {"Citation": "Schaefer D., Cheng X. Recent Advances in Covalent Drug Discovery. Pharmaceuticals. 2023;16:663. doi: 10.3390/ph16050663.", "ArticleIdList": ["10.3390/ph16050663", "PMC10220821", "37242447"]}, {"Citation": "McDonald S.M. RNA synthetic mechanisms employed by diverse families of RNA viruses. WIREs RNA. 2013;4:351\u2013367. doi: 10.1002/wrna.1164.", "ArticleIdList": ["10.1002/wrna.1164", "PMC7169773", "23606593"]}, {"Citation": "Uma Reddy B., Routhu N.K., Kumar A. Multifaceted roles of plant derived small molecule inhibitors on replication cycle of SARS-CoV-2. Microb. Pathog. 2022;168:105512. doi: 10.1016/j.micpath.2022.105512.", "ArticleIdList": ["10.1016/j.micpath.2022.105512", "PMC8976571", "35381324"]}, {"Citation": "Strelow J.M. A Perspective on the Kinetics of Covalent and Irreversible Inhibition. SLAS Discov. 2017;22:3\u201320. doi: 10.1177/1087057116671509.", "ArticleIdList": ["10.1177/1087057116671509", "27703080"]}, {"Citation": "La Monica G., Bono A., Lauria A., Martorana A. Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure\u2013Activity Relationship Insights and Evolution Perspectives. J. Med. Chem. 2022;65:12500\u201312534. doi: 10.1021/acs.jmedchem.2c01005.", "ArticleIdList": ["10.1021/acs.jmedchem.2c01005", "PMC9528073", "36169610"]}, {"Citation": "Shindo N., Ojida A. Recent progress in covalent warheads for in vivo targeting of endogenous proteins. Biorg. Med. Chem. 2021;47:116386. doi: 10.1016/j.bmc.2021.116386.", "ArticleIdList": ["10.1016/j.bmc.2021.116386", "34509863"]}, {"Citation": "Kovacic F., Mandrysch A., Poojari C., Strodel B., Jaeger K.-E. Structural features determining thermal adaptation of esterases. Protein Eng. Des. Sel. 2016;29:65\u201376. doi: 10.1093/protein/gzv061.", "ArticleIdList": ["10.1093/protein/gzv061", "PMC5943684", "26647400"]}, {"Citation": "Dong Y.-W., Liao M.-l., Meng X.-L., Somero G.N. Structural flexibility and protein adaptation to temperature: Molecular dynamics analysis of malate dehydrogenases of marine molluscs. Proc. Natl. Acad. Sci. USA. 2018;115:1274\u20131279. doi: 10.1073/pnas.1718910115.", "ArticleIdList": ["10.1073/pnas.1718910115", "PMC5819447", "29358381"]}, {"Citation": "Aouidate A., Ghaleb A., Chtita S., Aarjane M., Ousaa A., Maghat H., Sbai A., Choukrad M.b., Bouachrine M., Lakhlifi T. Identification of a novel dual-target scaffold for 3CLpro and RdRp proteins of SARS-CoV-2 using 3D-similarity search, molecular docking, molecular dynamics and ADMET evaluation. J. Biomol. Struct. Dyn. 2021;39:4522\u20134535. doi: 10.1080/07391102.2020.1779130.", "ArticleIdList": ["10.1080/07391102.2020.1779130", "PMC7309310", "32552534"]}, {"Citation": "Mathpal S., Joshi T., Sharma P., Joshi T., Pundir H., Pande V., Chandra S. A dynamic simulation study of FDA drug from zinc database against COVID-19 main protease receptor. J. Biomol. Struct. Dyn. 2022;40:1084\u20131100. doi: 10.1080/07391102.2020.1821785.", "ArticleIdList": ["10.1080/07391102.2020.1821785", "PMC7544932", "32940134"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "10", "Day": "10"}, {"Year": "2023", "Month": "10", "Day": "26"}, {"Year": "2023", "Month": "10", "Day": "28"}, {"Year": "2023", "Month": "11", "Day": "27", "Hour": "12", "Minute": "44"}, {"Year": "2023", "Month": "11", "Day": "25", "Hour": "12", "Minute": "46"}, {"Year": "2023", "Month": "11", "Day": "25", "Hour": "1", "Minute": "30"}, {"Year": "2023", "Month": "10", "Day": "30"}], "PublicationStatus": "epublish", "ArticleIdList": ["38005857", "PMC10675690", "10.3390/v15112175", "v15112175"]}}], "PubmedBookArticle": []}